Research Square
March 31, 2026
Marcus W. Meinhardt, Ivan Skorodumov, Florian Walter et al.
Abstract Alcohol use disorder is a major global health problem, and current treatments often fail to produce lasting reductions in harmful drinking1,2. Psychedelic-assisted therapies may promote durable behavioural change by enhancing brain plasticity during emotionally meaningful experiences, but progress has been limited by a lack of experimental models that capture these context-dependent...
bioRxiv (Cold Spring Harbor Laboratory)
March 24, 2026
Kenneth Shinozuka, Mattia Rosso, Anna Chaiken et al.
1 citation
Abstract Post-traumatic stress disorder (PTSD) is a debilitating condition that affects millions of veterans. A recent observational study in 30 veterans showed that a single dose of the atypical psychedelic ibogaine can be highly effective at treating PTSD up to twelve months later. Although a prior study demonstrated that ibogaine transiently alters electroencephalography (EEG) power in...
Journal of Psychedelic Studies
March 9, 2026
Genís Ona, Sidsel Marie
Abstract Background and aims Ibogaine, one of the oldest psychedelic alkaloids introduced to Western society and medicine, has a largely overlooked history prior to Howard Lotsof's accidental identification of its anti-addictive properties in the 1960s. This manuscript explores some previously hidden aspects of ibogaine, with a focus on the entangled cultural, colonial, and scientific histories...
Planta Medica
March 1, 2026
K Knížková, D Lovás, R Batelková et al.
Tabernanthe iboga is a plant containing a broad spectrum of alkaloids, the most significant of which is ibogaine. This alkaloid has been proven effective in the treatment of addiction to various substances, as it alleviates withdrawal symptoms and reduces cravings. Due to these properties, ibogaine clinics have emerged worldwide, incorporating ibogaine into treatment programs. [ 1 ] [ 2 ]...
Addiction Biology
March 1, 2026
Isis Koutrouli, Vojtěch Brejtr, Marek Schwendt et al.
Psychedelics have emerged as potential therapeutics for substance use disorders, yet preclinical data validating their efficacy remain limited. Here, we investigated the effects of a clinically inspired dose-escalation protocol of psilocybin and ibogaine on extinction and cue-induced reinstatement in Wistar male rats following intravenous cocaine self-administration (IVSA). Rats were trained on...